Search Results 1701-1710 of 4048 for Solid
Subject must have at least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Melanoma subjects ...
Has had an allogenic tissue/solid organ transplant. Has ongoing sensory or motor neuropathy Grade 2 or higher. Has active keratitis (superficial punctate ...
Presence of measurable lesions (as per Response Evaluation Criteria in Solid Tumors [RECIST]1.1); generally a ≥ 10 mm tumor lesion (in the longest diameter ...
Patients who have had allogeneic SCT/solid organ transplant. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team ...
Patients with a history of solid organ transplantation; Patients with a history of myocardial infarction, coronary re-vascularization procedures (including ...
... Solid Tumors version 1.1 (RECIST 1.1) after initial treatment. Safety and Durability of Sirolimus for Treatment of LAM. Rochester, Minn., Jacksonville, Fla ...
solid agar 4. Is either treatment naïve and has not received any prior treatment for MAC, OR if previously treated for MAC and meets all of the following ...
- Kidney or any other solid organ transplant recipient or a planned transplant during the study; - Acute dialysis or acute kidney injury within 12 weeks ...
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.